192 related articles for article (PubMed ID: 21407047)
1. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Devanand DP; Mintzer J; Schultz S; Sultzer D; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Andrews H; Levin B
Am J Geriatr Psychiatry; 2012 Apr; 20(4):362-73. PubMed ID: 21407047
[TBL] [Abstract][Full Text] [Related]
2. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
3. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
[TBL] [Abstract][Full Text] [Related]
4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.
Patel AN; Lee S; Andrews HF; Pelton GH; Schultz SK; Sultzer DL; Mintzer J; de la Pena D; Gupta S; Colon S; Schimming C; Levin B; Devanand DP
Am J Psychiatry; 2017 Apr; 174(4):362-369. PubMed ID: 27855483
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
9. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of risperidone in Alzheimer's disease.
Ling SM; Bonner AF; McMullen TL
N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
[No Abstract] [Full Text] [Related]
11. Discontinuation of risperidone in Alzheimer's disease.
Power GA
N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
[No Abstract] [Full Text] [Related]
12. Discontinuation of risperidone in Alzheimer's disease.
Gnjidic D; Hilmer SN
N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
[No Abstract] [Full Text] [Related]
13. Discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Schultz SK; Sultzer DL
N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
[No Abstract] [Full Text] [Related]
14. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
16. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
Mintzer J; Greenspan A; Caers I; Van Hove I; Kushner S; Weiner M; Gharabawi G; Schneider LS
Am J Geriatr Psychiatry; 2006 Mar; 14(3):280-91. PubMed ID: 16505133
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
[TBL] [Abstract][Full Text] [Related]
20. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
